ImetelChat

According to AF - the Novartis/Morphosys isn't happening......

https://www.statnews.com/2024/02/06/why ... morphosys/

Bp - this article shines a little more light on the finer details....... "Pelabresib plus Jakafi recently met the primary endpoint of spleen volume reduction in the phase 3 MANIFEST-2 study in myelofibrosis patients who’ve never tried a JAK inhibitor, Novartis and MorphoSys pointed out in their M&A ...

My take - not that it means anything: Novartis wants in on the MF market. They were at the Geron table in 2020 (speculation on my part based on the EA hire from Novartis who returned immediately after meetings with the FDA). For some unknown reason they walked. Imetelstat is worth quite a bit more t...

Someone on the YMB had mentioned that March 14 is the day before quadruple witching? -Kmall

Big Pharma may need Geron a little sooner than Geron needs them.......they may want to get in before they fall off the patent cliff??...... would never think of making fun of anyone making predictions around here. -Kmall https://www.google.com/amp/s/www.cnbc.com/amp/2024/01/28/big-pharma-merck-brist...

Here's a link..... https://www.fiercepharma.com/special-reports/top-10-most-anticipated-drug-launches-2024 10. Imetelstat By Nick Paul Taylor Drug: Imetelstat Company: Geron Used for: Lower-risk myelodysplastic syndromes Est. 2028 sales: $737 million "After more than 30 years of work, Geron is less ...

Looks like this is unwinding even more......

https://fortune.com/europe/2024/01/29/h ... ogger/amp/

Bp - that is rather cringeworthy.

Ryan had posted an article about fabrications of scientific/medical papers earlier this week, which focused on Dana-Faber Cancer Institute - a medical branch of Harvard University. This one is a little more in-depth. -Kmall

https://www.nbcnews.com/news/amp/rcna135521

https://www.reuters.com/business/health ... 024-01-23/

The following will all get a warning label:

Bristol Myers Squibb's - Breyanzi and Abecma

J&J/Janssen - Carvykti

Novartis - Kymriah

Gilead - Tecartus and Yescarta.

RC - did you get a date on that post?

Honestly Bp, it's been so long and so much aqua under this bridge it's hard to keep track.....the Land Ho thing was a nod to Jingle, who deserves to see this come to fruition more than anyone else I can think of. With that said, I did read your reply this morning on the YMB, and I should have been a...

Alex Sardinas - Regional Business Director Northeast, Geron Corporation Hired - January 2024 Former employers: Incyte, CITI BioPharma, Boehringer Ingelheim, Bristol-Meyers Squibb, Janssen, GlaxoSmithkline, Sprint Greg Titone - Regional Business Director Gulf Coast, Geron Corporation Hired - January ...

Bp - yes to infusion.....my mistake. And I think you basically answered my question, which was poorly structured to begin with. It is difficult to come to any concrete answers on the subject since it's still a work in progress with each patient example different. Thank you for taking the time to sor...

Of course every patient and situation is unique, but it is noteworthy that this patient has an Imetelstat transfusion every 4 weeks for the past year. Do we have any idea how long a patient like the one described here needs to be getting transfusions, and do the patients transfusions diminish over a...

I can't think of a better endorsement for the patient community then this. I would imagine that this sort of testimony spreads like fire amongst these groups. Simply incredible that Imetelstat hadn't received priority review or accelerated approval. -Kmall

Bp - It was mentioned that this post on Stocktwits was reposted from the MDS Facebook group.

Sidenote on most/all of the latest hires the past two months...... they're all coming directly from positions at Big Pharma - Novartis, Incyte, Jazz, Bristol Meyers - just to name a few. -Kmall

Bp - Thanks!

Bp - noticed this link earlier on the YMB. This was presented at ASH last month. Is there something new here I'm missing? -Kmall